Commercial dose companies form a critical component of the pharmaceutical manufacturing industry’s value chain. Commercial dose form manufacturing follows API manufacturing to produce the final dosage ...

Clinical laboratory lobbying groups are suing the FDA over its plans to more strictly regulate lab-developed tests. For now, ...

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Serán Bioscience ("Serán" or "the Company"), a leading contract development and manufacturing organization (CDMO) providing a ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Based on an Avalere Health report, Community Oncology Alliance warns that IRA negotiations could slice down payments needed ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...